Hosted on MSN1d
UBS Downgrades Novartis AG - Depositary Receipt () (NVS)
Fintel reports that on February 13, 2025, UBS downgraded their outlook for Novartis AG - Depositary Receipt () (NYSE:NVS) ...
Switzerland’s pharmaceutical industry faces new threat as Trump eyes tariffs
U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...
UBS cuts Novartis stock rating, lowers price target to CHF104
UBS analyst Matthew Weston downgraded Novartis (SIX:NOVN) shares from Buy to Neutral and reduced the price target from CHF111 ...
UBS downgrades Novartis AG (NOVN) to a Hold
In a report released today, Matthew Weston from UBS downgraded Novartis AG (NOVN – Research Report) to a Hold, with a price target of ...
EuropaWire2d
Novartis Acquires Anthos Therapeutics to Advance Abelacimab in Stroke and Thrombosis Prevention
Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...
Novartis buying US biotech company
Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.
Nature2d
Dozens of new obesity drugs are coming: these are the ones to watch
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...
PipelineReview.com3d
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
BASEL, Switzerland I 11, 2025 I Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, ...